Abstract
Purpose
To evaluate central corneal thickness (CCT) and intraocular pressure (IOP) in a cohort of acromegalic patients, and to correlate CCT with serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
Methods
Consecutive patients affected by acromegaly underwent a comprehensive endocrinological and ophthalmological evaluation, including serum GH and IGF-1 levels, CCT measured with ultrasonic pachymetry and IOP assessed with Goldmann applanation tonometry.
Results
Fourteen patients with acromegaly and 28 healthy controls were included in the study. Acromegalic patients had a statistically higher median CCT (570 μm [range 551.5–638] vs 542.7 μm [range 461.5–610]; p < 0.01) and higher median IOP (17.2 mm Hg [range 14–21] vs 13.7 mm Hg [range 10.5–19]; p < 0.01) than healthy controls. No statistically significant correlation was found among CCT and GH, CCT and IGF-1, IOP and GH, IOP and IGF-1 in the acromegalic group, whereas a statistically significant correlation was documented between CCT and IOP in the entire cohort (Spearman’s correlation coefficient: 0.56, p < 0.01). However, when IOP was corrected for CCT no significant difference was found between the two study groups (p = 0.07).
Conclusions
Our results suggest that acromegaly is associated with an increased CCT, which could lead to an overestimation of IOP readings as determined with Goldmann applanation tonometry.
Similar content being viewed by others
References
Melmed S (2006) Medical progress: Acromegaly. N Engl J Med 355(24):2558–2573. doi:10.1056/NEJMra062453
Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S, Pituitary S (2003) The European Neuroendocrine: a diagnosis and treatment of acromegaly complications. J Endocrinol Investig 26(12):1242–1247
Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294–302. doi:10.1007/s11102-012-0420-x
Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A, Giampietro A, De Marinis L, Giustina A (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98(8):3402–3410. doi:10.1210/jc.2013-1460
Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol 72(2):203–208. doi:10.1111/j.1365-2265.2009.03626.x
Heireman S, Delaey C, Claerhout I, Decock CE (2011) Restrictive extraocular myopathy: a presenting feature of acromegaly. Indian J Ophthalmol 59(6):517–519. doi:10.4103/0301-4738.86330
Parentin F, Pensiero S (2010) Central corneal thickness in children with growth hormone deficiency. Acta Ophthalmol (Copenh) 88(6):692–694. doi:10.1111/j.1755-3768.2009.01519.x
Hellstrom A, Svensson E, Carlsson B, Niklasson A, Albertsson-Wikland K (1999) Reduced retinal vascularization in children with growth hormone deficiency. J Clin Endocrinol Metab 84(2):795–798
Bourla DH, Laron Z, Snir M, Lilos P, Weinberger D, Axer-Siegel R (2006) Insulinlike growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome. Ophthalmology 113(7):1197.e1–1197.e5. doi:10.1016/j.ophtha.2005.12.023
Howard GM, English FP (1965) Occurrence of glaucoma in acromegalics. Arch Ophthalmol 73:765–768
Aren A, Skanse B (1955) On non-inflammatory glaucoma in acromegaly. Acta Ophthalmol (Copenh) 33(3):295–306
Bramsen T, Klauber A, Bjerre P (1980) Central corneal thickness and intraocular tension in patients with acromegaly. Acta Ophthalmol (Copenh) 58(6):971–974
Greco AV, Ricci B, Altomonte L, Rebuzzi AG, Manna R, Ghirlanda G (1979) GH secretion in open-angle glaucoma. Ophthalmologica 179(3):168–172
Ciresi A, Amato MC, Morreale D, Lodato G, Galluzzo A, Giordano C (2011) Cornea in acromegalic patients as a possible target of growth hormone action. J Endocrinol Investig 34(2):e30–e35. doi:10.3275/7205
Polat SB, Ugurlu N, Ersoy R, Oguz O, Duru N, Cakir B (2013) Evaluation of central corneal and central retinal thicknesses and intraocular pressure in acromegaly patients. Pituitary [Epub ahead of print]. doi:10.1007/s11102-013-0505-1
Ehlers N, Bramsen T, Sperling S (1975) Applanation tonometry and central corneal thickness. Acta Ophthalmol (Copenh) 53(1):34–43
Herndon LW, Choudhri SA, Cox T, Damji KF, Shields MB, Allingham RR (1997) Central corneal thickness in normal, glaucomatous, and ocular hypertensive eyes. Arch Ophthalmol 115(9):1137–1141
Doughty MJ, Zaman ML (2000) Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol 44(5):367–408
Wolfs RC, Klaver CC, Vingerling JR, Grobbee DE, Hofman A, de Jong PT (1997) Distribution of central corneal thickness and its association with intraocular pressure: the Rotterdam Study. Am J Ophthalmol 123(6):767–772
Argus WA (1995) Ocular hypertension and central corneal thickness. Ophthalmology 102(12):1810–1812
De Moraes CG, Juthani VJ, Liebmann JM, Teng CC, Tello C, Susanna R Jr, Ritch R (2011) Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol 129(5):562–568. doi:10.1001/archophthalmol.2011.72
Medeiros FA, Weinreb RN (2012) Is corneal thickness an independent risk factor for glaucoma? Ophthalmology 119(3):435–436. doi:10.1016/j.ophtha.2012.01.018
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metabol 85(2):526–529
Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S, Acromegaly Consensus G (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metabol 95(7):3141–3148. doi:10.1210/jc.2009-2670
Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus G (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metabol 94(5):1509–1517. doi:10.1210/jc.2008-2421
Whitacre MM, Stein R (1993) Sources of error with use of Goldmann-type tonometers. Surv Ophthalmol 38(1):1–30
Youngster I, Rachmiel R, Pinhas-Hamiel O, Bistritzer T, Zuckerman-Levin N, de Vries L, Naugolny L, Eyal O, Braunstein R, Rachmiel M (2012) Treatment with recombinant human growth hormone during childhood is associated with increased intraocular pressure. J Pediatr 161(6):1116–1119. doi:10.1016/j.jpeds.2012.05.024
Ozkok A, Hatipoglu E, Tamcelik N, Balta B, Gundogdu AS, Ozdamar MA, Kadioglu P (2014) Corneal biomechanical properties of patients with acromegaly. Br J Ophthalmol 98(5):651–657. doi:10.1136/bjophthalmol-2013-304277
Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metabol 94(5):1500–1508. doi:10.1210/jc.2008-2332
Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7(5):e36411. doi:10.1371/journal.pone.0036411
Giustina A, Karamouzis I, Patelli I, Mazziotti G (2013) Octreotide for acromegaly treatment: a reappraisal. Expert Opin Pharmacother 14(17):2433–2447. doi:10.1517/14656566.2013.847090
Acknowledgments
None
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Quaranta, L., Riva, I., Mazziotti, G. et al. Elevated intraocular pressure in patients with acromegaly. Graefes Arch Clin Exp Ophthalmol 252, 1133–1139 (2014). https://doi.org/10.1007/s00417-014-2650-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-014-2650-2